Novocure Limited
A maker of cancer treatments that harness electricity rather than drugs, Novocure produces the Optune device, a wearable system that delivers low-intensity electric fields (called Tumor Treating Fields) to slow tumor growth in adults with glioblastoma, an aggressive brain cancer. It was founded in 2000 by Yoram Palti, a biophysicist who first tested his theory in a lab he set up in the basement of his home in Israel.
Granted 207.4K
Bought 125.0K · Sold 676.6K
Sold 1.07M
Granted 147.8K · Sold 777.8K
Granted 2.07M
Granted 619.7K · Sold 239.8K
Granted 424.7K · Bought 81.5K · Sold 60.0K
Granted 3.16M · Bought 15.0K · Sold 3.68M
Granted 1.16M · Sold 1.05M
Granted 303.7K · Sold 60.4K
Granted 225.6K
Granted 1.37M · Sold 1.06M
Granted 314.2K · Sold 104.9K
Granted 206.8K · Sold 4.7K
Granted 1.35M · Sold 893.4K
Granted 110.1K · Bought 20.0K · Sold 6.4K
Bought 20.0K
Granted 1.00M · Sold 834.2K
Granted 471.8K · Sold 352.5K
Granted 106.1K · Sold 3.1K
Granted 489.0K · Sold 387.9K
Granted 130.2K · Sold 55.8K
Granted 51.1K
Granted 48.9K · Sold 8.7K
Granted 396.4K · Sold 335.9K
Granted 3.3K
Granted 36.0K · Sold 3.9K
Granted 31.7K · Sold 1.0K
Granted 64.7K · Sold 44.4K
Granted 30.7K · Sold 4.9K
Granted 33.6K · Sold 6.9K
Granted 26.9K · Sold 3.9K
Granted 26.9K · Sold 3.9K
Granted 6.7K
Granted 6.1K
Granted 176.6K · Sold 173.2K
Granted 2.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Wyss Hansjoerg10% owner · 3 transactions | — | 9.78Mas of Dec 2019 | — | — | — |
| Perlhagen Gert L. +1 co-filerDirector, 10% owner, 10% owner · 3 transactions | — | 7.89Mas of May 2016 | 207.4K | — | — |
| Volati Ltd10% owner · 1 transaction | — | 7.22Mas of Aug 2016 | — | — | — |
| Perlhagen Gert L.Director · 11 transactions | — | 6.13Mas of Mar 2017 | — | 125.0K | 676.6K |
| Futrell Steve +7 co-filers10% owner · 4 transactions | — | 6.06Mas of Jun 2017 | — | — | 1.07M |
| Palti YoramChief Technology Officer, Director · 75 transactions | — | 1.04Mas of Aug 2018 | 147.8K | — | 777.8K |
| Doyle William F +1 co-filerExecutive Chairman, Director, 10% owner, 10% owner · 12 transactions | — | 923.1Kas of Mar 2017 | 2.07M | — | — |
| Leonard Frank XChief Executive Officer · 87 transactions | — | 459.5K | 619.7K | — | 239.8K |
| Cordova AshleyFormer Chief Executive Officer · 64 transactions | — | 422.6K | 424.7K | 81.5K | 60.0K |
| Danziger AsafDirector · 156 transactions | — | 416.5K | 3.16M | 15.0K | 3.68M |
| Groenhuysen Wilhelmus CMChief Operating Officer · 259 transactions | — | 376.7Kas of Jun 2024 | 1.16M | — | 1.05M |
| Weinberg UriChf Medical and Innovation Ofr · 37 transactions | — | 267.2K | 303.7K | — | 60.4K |
| Ben Arye BarakGeneral Counsel · 13 transactions | — | 242.5K | 225.6K | — | — |
| Ambrogi Michael J.Chief Operating Officer · 122 transactions | — | 220.9Kas of Jul 2020 | 1.37M | — | 1.06M |
| Vernon W AnthonyDirector · 14 transactions | — | 209.3K | 314.2K | — | 104.9K |
| Puri Michal NathChief Human Resources Officer · 13 transactions | — | 201.3K | 206.8K | — | 4.7K |
| Doyle William FExecutive Chairman, Director · 78 transactions | — | 200.0K | 1.35M | — | 893.4K |
| Brackmann ChristophChief Financial Officer · 7 transactions | — | 182.8K | 110.1K | 20.0K | 6.4K |
| Mylod Robert J JrDirector · 2 transactions | — | 168.1Kas of Mar 2016 | — | 20.0K | — |
| Kirson Eilon D.Chief Science Officer · 39 transactions | — | 152.4Kas of Feb 2019 | 1.00M | — | 834.2K |
| Shah PriteshChief Growth Officer · 125 transactions | — | 124.5Kas of Nov 2023 | 471.8K | — | 352.5K |
| Leupin NicolasFormer Chief Medical Officer · 6 transactions | — | 103.0K | 106.1K | — | 3.1K |
| Leung GabrielDirector · 100 transactions | — | 101.1K | 489.0K | — | 387.9K |
| Paravasthu MukundChief Operating Officer · 18 transactions | — | 72.8K | 130.2K | — | 55.8K |
| Giladi MosheChief Science Officer · 1 transaction | — | 69.8Kas of Feb 2024 | 51.1K | — | — |
| Burke William PatrickChief Human Resources Officer · 19 transactions | — | 66.4Kas of Jun 2023 | 48.9K | — | 8.7K |
| Longsworth Todd ChristopherGeneral Counsel · 83 transactions | — | 62.5Kas of Mar 2022 | 396.4K | — | 335.9K |
| Langloss Timothy J.Director · 1 transaction | — | 35.5Kas of May 2016 | 3.3K | — | — |
| Hung DavidDirector · 9 transactions | — | 32.1K | 36.0K | — | 3.9K |
| Madden Martin J.Director · 10 transactions | — | 30.3K | 31.7K | — | 1.0K |
| Benaim ElyChief Medical Officer · 45 transactions | — | 28.8Kas of Jan 2023 | 64.7K | — | 44.4K |
| Scannell Timothy JDirector · 7 transactions | — | 25.9K | 30.7K | — | 4.9K |
| Hilleman Jeryl LDirector · 11 transactions | — | 25.5K | 33.6K | — | 6.9K |
| Ocean Allyson JDirector · 5 transactions | — | 22.9K | 26.9K | — | 3.9K |
| Stafford KristinDirector · 5 transactions | — | 22.9K | 26.9K | — | 3.9K |
| Lavigne Louis J JrDirector · 1 transaction | — | 7.4Kas of Oct 2015 | — | — | — |
| McCoy Sherilyn SDirector · 3 transactions | — | 6.7Kas of Jun 2021 | 6.7K | — | — |
| Burkoth William T.Director · 1 transaction | — | 6.1Kas of May 2019 | 6.1K | — | — |
| Phillips Charles G IIIDirector · 19 transactions | — | 3.4Kas of Dec 2019 | 176.6K | — | 173.2K |
| Melnyk Peter M.Chief Commercial Officer · 1 transaction | — | 2.4Kas of Jan 2017 | 2.4K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -11.65M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.